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Introduction
The value and utility of patient registries are largely contingent
upon the use of both high-quality research questions and
structured and relevant answer sets accompanying them. The
interoperability of registries or registry data—including the
feeding of registry data into more rigorous clinical studies and
regulatory submissions for new agents—depends upon the use
of data standards; yet, there is currently no clear specification
for developing registry questions nor are there banks of existing
questions to support registry developers. The diverse nature of
registries, sponsors, and disease-specific data requirements
complicate efforts at standardization in registry applications.
This paper introduces the [Rare Disease] PRISM (Patient
Registry Item Specifications and Metadata for Rare Disease)
project, a library of standardized questions covering a broad
spectrum of rare diseases that can be used to support the
development of new registries in all disease areas. If widely
used, PRISM will enable the re-use of questions across
registries, hence reducing the variation in registry data collection
and facilitating a bottom-up standardization of patient registries.
Although it was developed to support the rare disease
community’s urgent need for shared resources, the PRISM
library of patient-directed registry questions can be a valuable
resource to registries for all diseases.
Background
Rare Diseases Registries
Often patient registries are a helpful first step in estimating the
impact and understanding the etiology of rare diseases—both
requisites for the development of new diagnostics and
therapeutics. Because of the small numbers of patients affected
by rare diseases, these registries present unique challenges
related to registry design, enrollment of patients, and data
collection [1-5], as well as for analysis and interpretation of
registry data [5,6]. In recent years, the U.S. Food and Drug
Administration (FDA) and umbrella patient advocacy support
organizations (eg, the Genetic Alliance) have publicly
encouraged rare disease patient advocacy groups (PAGs) to
develop registries as part of a comprehensive strategic research
plan. As such, a proliferation of patient registries is underway,
and there are currently no dedicated or centralized efforts for
developing standards that will reduce the time required to
develop new patient registries and facilitate opportunities for
shared data.
Patient Registry Variation and Standards
There is tremendous variability in the type of data and specific
questions that patient registries collect, due in part to the lack
of registry-specific data standards and also to the heterogeneity
of registries’ purposes and sponsors. Patient registries can be
designed for many purposes, including public health
surveillance, epidemiologic and longitudinal research, patient
education, research recruitment, and population monitoring for
the safety of post-marketed drugs and devices. Patient registries
can include data reported by patients, researchers, or clinicians.
(A characterization of registry types is summarized in Richesson
and Vehik [2].) Sponsors and developers of patient registries
are varied as well and include governments, academic scientists,
and clinical investigators. Often patient registries (and the
supporting questions, typically targeted to patients and
caregivers rather than physicians) are developed ad hoc by the
PAGs themselves, and there is currently no clear specification
for standards or banks of existing questions for them to access.
Further, the content of these registries (ie, the questions and
associated answer sets) may change over time as more becomes
known about the disease and its clinical variations, or when
new therapeutics and devices become available. There is a
tremendous need—especially for the thousands of rare diseases
that do not have patient registries—for resources that help
registry sponsors and developers to identify well-constructed
and meaningful questions.
There is also a clear role for data standards to promote shared
efficiencies in registry development and enable opportunities
for data sharing. These needs are particularly pronounced for
rare diseases, which have sparse resources and significantly
fewer—and highly distributed—domain experts and affected
patients. An important standards challenge is the fact that there
is no central control of patient registries—there is no single
funding or regulatory agency that can oversee all the different
registry types and implementations. Because registries are
developed by many sponsors to address distinct functions, a
top-down standards effort would require countless stakeholders
and is not feasible. Additionally, there is no central authority
to monitor or enforce standards compliance once developed.
Given the tremendous need for standards and the scope of data
collected across disease-specific registries, and given that there
is no incentive or regulatory means to develop standards or
enforce compliance, alternatives to complement traditional
Standards Development Organizations (SDOs) are needed.
Non-traditional strategies for developing and promoting
standards can be effective and embraced across various rare
diseases if these various research communities perceive them
as accessible, useful, helpful, and easy to adopt.
The PRISM project (funded by an American Recovery and
Reinvestment Act (ARRA) grant administered through the
National Library of Medicine (NIH), NLM Grant Number
1RC1LM010455-01, and supported by the Office of Rare
Diseases Research) was developed to provide a useful resource
to promote the efficient development of patient registries and
standardized quality data collection by supporting the sharing
and re-use of existing registry questions and data standards. The
fundamental idea behind PRISM is that if registry developers
could access questions used by other rare disease registries, they
could consider and likely re-use these questions, thereby
reducing the variation in questions/data collection across various
patient registries, and leading to a bottom-up development of
standards. In addition, the utility and scalability of PRISM is
based on the notion that the PRISM content is accessible and
open to any registry sponsor, regardless of prior standards
knowledge or experience. The authors are engaged with various
standards and informatics organizations and deliberately
designed PRISM to facilitate linkage with other standards and
research resources as appropriate. The PRISM project, therefore,
provides not only a library of questions but a vehicle for the
registry developers and rare disease organizations to interact,
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learn, and develop consensus requirements, which can in turn
be directed to various standards development organizations (eg,
CDISC [7], HL7 [8], LOINC [9]), research initiatives (eg,
caDSR [10] and CSHARE, PROMIS [11,12], PhenX [13]), and
national interoperability initiatives emerging from the U.S.
DHHS, Office of the National Coordinator [14,15].
As a demonstration project, PRISM explored foundational issues
related to the types of questions included in the bank (relative
to other standards and question repositories) and the inclusion
of metadata that will facilitate their search and retrieval. We
describe our methodological approach to developing the PRISM
library in the Methods section and present the resulting library
structure, features, and composition afterward in the Results
section.
Methods
The first questions identified for PRISM included a convenience
sample of questions from well-established (>5 years) natural
history studies in various diseases (metabolic [16], vascular
[17], developmental disorders [18]) and several existing
registries. The questions were obtained largely from the
NIH-funded Rare Diseases Clinical Research Network as the
authors worked in the data center for the network and had
familiarity with the various studies and investigators. These
were examined by many experts (both terminology experts at
the College of American Pathologists (CAP) and research and
informatics experts at the University of South Florida (USF))
for face validity, including commonality, clarity, and
organization. Questions were re-worded slightly, as needed, to
make the full semantics of the question clear and to make the
question generalizable to multiple diseases as possible. For
example, a registry data entry item “Genetic test?” would be
entered into PRISM as “Have you had a genetic test to confirm
your diagnosis?”, representing the intended semantics of the
question in a generalizable way, rather than “Have you had a
genetic test to confirm your Rett Syndrome diagnosis?”, which
was the intent of the question from the source document. In
addition, some registry questions were taken from a variety of
established rare disease patient registries that authors were
acquainted with. To ensure that questions were “stable” and
field-tested, authors used well-established content that had been
considered final by a PAG after a multi-disciplinary review
process and pilot testing. Generic content relative to many or
all patient registries was also incorporated, including standard
elements from the Rare Diseases Clinical Research Network
(RDCRN) Contact Registry (supporting over 200 rare diseases)
[19], the OMB and NIH demographics [20], selected questions
from the NINDS Common Data Elements [21], and all of the
data elements recommended for the Global Registry for Rare
Diseases [22], an initiative led by the U.S. Office of Rare
Diseases Research. A typology was developed to organize the
questions in PRISM and to support internal curation of the
library. Questions were indexed by one or more keywords that
describe the general content category (eg, demographic,
medications, medical history, special histories, etc.). The specific
representations of the metadata keywords include common
forms (eg, Demographics, Medical History) and form headings
(eg, Medication History, Special Education Services) that group
related data (by type or by source) for registries and
observational studies.
We describe our selected strategy and design features for PRISM
in the next section in terms of content, search and retrieval
requirements, indexing model and metadata, and strategy for
growing the content of the PRISM library. The authors
thoroughly explored other standards throughout the design of
PRISM and present the relationships and definitions between
PRISM and other efforts related to standardized questions and
patient reported data. Finally, in the discussion section, we
describe immediate future directions for PRISM, including
requirements for sharing the library, interface design, and future
plans for maintenance and governance of PRISM.
Results
Content
At present, PRISM contains over 2,200 questions. A sample of
224 questions and selected metadata is presented in Appendix
1. Many questions (especially the most general, such as “List
current medications you are taking” and “List any other major
diseases you have had”) are relevant to virtually all rare diseases,
and others are relevant to a great many rare diseases (eg, “Do
you require an assistive device for walking?”, or “Was your
child born full-term?”). However, the majority of PRISM
questions—such as “Does your child hoard food?”, “How many
times per week does child pick at own skin until it bleeds?”,
“Does your child need TV to fall asleep?”, and “Approximately
how many bone fractures have you had in your lifetime?”—are
relevant only to particular diseases, and often the valid answer
sets associated with each question are disease-specific. For
example, valid answers to the question “What age was your
child’s first bone fracture?” would include prenatal ages in a
patient registry targeted to Osteogenesis Imperfecta, thereby
requiring different units and ranges of expected values. The
obvious challenge that thousands of such disease-specific
questions (relevant to the thousands of rare diseases seeking to
develop registries) will present for traditional standards
development organizations is what drove the design decision
for the scope of PRISM. The scope of PRISM, therefore,
deliberately includes a range of disease-specific content, along
with narrative definitions and metadata for indexing and source
preservation. The metadata was selected to facilitate linkages
between rare disease communities and existing SDOs and
controlled terminologies, as described in the following sections.
Related Efforts
To prevent overlapping with other standards efforts related to
the collection of clinical data, a deliberate search for relevant
standardization efforts was undertaken by the authors. This
search of existing standards and informatics and library
resources revealed several related and potentially relevant
efforts, and informed the design of PRISM to leverage related
efforts. As described in the introduction, the focus of PRISM
is on patient-reported questions that are not a part of
standardized, validated patient assessment instruments. Given
that focus, several organizations are engaged in various attempts
to inventory and codify standardized assessment instruments
and items, specifically Clinical LOINC [23], PROMIS, the
Interact J Med Res 2012 | vol. 1 | iss. 2 | e10 | p.3http://www.i-jmr.org/2012/2/e10/
(page number not for citation purposes)
Richesson et alINTERACTIVE JOURNAL OF MEDICAL RESEARCH
XSL•FO
RenderX
caDSR and NINDS Common Data Elements [24], and to some
extent SNOMED CT. Because PRISM was developed with the
intent to leverage and coordinate existing standards as much as
possible, the PRISM scope was clearly defined at the onset to
prevent any overlap. However, some areas of potential overlap
with other initiatives exist. Table 1 and Table 2 describe the
potential relationship of PRISM to other initiatives that are also
developing repositories of questions or data elements.
Table 1. Relationship of PRISM to Related Standards Efforts and Resources (LOINC, caDSR, and PhenX).
Proposed relationship with PRISMScope of standardObjectivePrimary SponsorInitiativea
Patient assessment scales are not generally included
in PRISM. PRISM documentation directs users to
LOINC for this content. [Note: Clinical LOINC
does not contain every assessment scale ever pub-
lished. Registry developers need to search Clinical
LOINC or RELMA.]
LOINC is interested in supporting electronic health
record (EHR) data standards. The rare disease
community should leverage LOINC to support
transfer of EHR data to registries. PRISM could
coordinate this.
The majority of PRISM content is variable and
might not be messaged or collected in EHRs. But,
some PRISM items can be submitted to LOINC if
appropriate. PRISM will filter and act as a feeder
of selected content into LOINC; PRISM definitions
and metadata will aid in this.
Health care (primari-
ly) and research
Messaging and interoperabil-
ity of clinical information.
Specifically, the LOINC
database provides a set of
universal names and ID
codes for identifying labora-
tory and clinical test results.
NLMClinical LOINC
http://www.webcita-
tion.org/6BJJ3JZIm
caDSR content and tools are targeted to clinical
researchers. Much of caDSR content could be rele-
vant to PRISM and rare disease registry developers,
but is not complete nor easily searchable by rare
disease users. PRISM includes a focus on registries
and rare diseases and a community forum for rare
disease registry standards.
PRISM maintains a link to source for all content.
Users can see explicit links to caDSR if that is the
source.
PRISM questions could be imported into caDSR
for use in clinical research projects. (The PRISM
metadata has enough detail to support their transfer
if caDSR curators want.)
Data elements for
collection in clinical
research studies.
NCI’s vocab ser-
vices and metadata
repositories do sup-
port diseases other
than cancer, and
have standard data
elements from FDA
and NIH institutes
and centers.
Research data elements.
“caDSR is a database and a
set of APIs and tools to cre-
ate, edit, control, deploy,
and find common data ele-
ments (CDEs) …for use in
software development.”
(CSHARE is expected to
emerge as an expanded pan-
disease version of the caD-
SR but is not yet available.)
NCIcaDSR (CSHARE)
http://www.webcita-
tion.org/6BJJ5fd1Y
Much of PRISM content is very disease specific,
often idiosyncharic, and not included in PhenX.
PhenX is consulted as a resource for generic ques-
tions, which were incorporated into PRISM when
authors thought appropriate (underlying PRISM
database includes PhenX code in these cases).
Where content overlap exists, PRISM points users
to PhenX measures. PhenX is aimed at researchers,
but user interface is intuitive and easily accessible
to PRISM users.
Data elements used
in new research data
collection, or
used/queried from
various electronic
health records.
Content focuses on
common diseases
but is growing.
To provide investigators
with high-quality, relatively
low-burden measures for in-
clusion in genome-wide as-
sociation studies (GWAS)
and other large-scale re-
search efforts.
National Human
Genome Research
Institute (NHGRI)
PhenX
http://www.webcita-
tion.org/6BJJ8xNzU
a These initiatives are not specific to patient registries or rare diseases.
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Table 2. Relationship of PRISM to Related Standards Efforts and Resources (PROMIS, SNOMED CT, RxNorm).
Proposed relationship with PRISMScope of StandardObjectivePrimary SponsorInitiativea
PRISM explicitly avoids content that is validated
and intended to be used for measurement.
Where there are common questions, PROMIS and
PRISM will cross-reference each other.
PRISM directs users to PROMIS and describes its
potential application in patient registries.
Functional and qual-
ity-of-life assess-
ment questions. Val-
idated measures on-
ly; focus on psy-
chosocial constructs
across domains, not
only specific dis-
eases.
A system of highly reliable,
precise measures of pa-
tient–reported health status
for physical, mental, and so-
cial well-being.
NIHPROMIS (Patient
Reported Outcomes
Measurement Infor-
mation System)
http://www.webcita-
tion.org/6BJIvffJ8
SCT is used for indexing in PRISM. Each PRISM
question associated with one or more codes that
best represent the important content of the PRISM
QAS. The most specific SCT code is used, with the
understanding that only some PRISM questions get
very precise representation in SCT. Similarly,
multiple SCT codes can be used to index the clinical
content of multi-concept questions.
[In 2006, the SCT nursing working group (prior to
the IHTSDO) developed a model for coding assess-
ment scales to SCT, which was approved by the
SCT International Editorial Board. So, SCT should
be added to the “specifically” list. The Observable
Entity-Answer approach to coding PRISM follows
the SCT model for coding assessments.]
Comprehen-sive
clinical terminology
covering nursing and
medical diagnoses,
signs and symptoms,
functional status, in-
terventions, proce-
dures, and outcomes.
Provides a consistent way to
index, store, retrieve, and
aggregate clinical data
across specialties and sites
of care.
Int’l. standards devel-
opment organisation
(IHTSDO) [Support-
ed by dues from
member nations]
US residents may
use SNOMED CT
free of charge, sup-
ported by NLM.
SNOMED CT
(SCT)
http://www.webcita-
tion.org/6BJIyeJ5C
RxNorm does not represent data elements but is a
nomenclature for clinical drugs. Many registries
ask questions about specific medications.
RxNorm is used for indexing questions about
medications in PRISM. Each medication-related
question in PRISM is associated with RxNorm
codes that best represent the named drug – either
by clinical drug name, (generic) ingredient, or
packaged products.
Standardized
nomenclature for
clinical drugs and
drug delivery de-
vices (mostly in
US); gives normal-
ized names for clini-
cal drugs and links
its names to many
drug vocabularies
used in pharmacy
management and
drug interaction
software.
RxNorm contains the names
of prescription and many
non-prescription formula-
tions in the US; aims to sup-
port electronic exchange of
medication information and
clinical decision support re-
lated to CPOE in health care
contexts.
NLMRxNorm
a These initiatives are not specific to patient registries or rare diseases.
Some data elements, like height and weight are in clinical data
element repositories such as Clinical LOINC and research data
element registries like caDSR. To enable “one-stop shopping”
for registry developers, these items are also in PRISM, with the
idea that future PRISM interfaces can identify linkages to these
other standards where and when appropriate. These linkages
can inform PRISM users that they indeed are using items from
another designated standard and can also inform PRISM curators
to ensure that they do not create or support future variations in
that item.
In the interest of rapidly assembling content relevant to patient
registries for any and all rare diseases, the initial PRISM strategy
has been to accept virtually all questions, with the idea that
either patient communities or curators might later filter, rate,
or rank them for PRISM users. Despite limiting the inclusion
of questions to those from well-established registries, some
questions used in rare disease registries were poorly constructed
or not as clear as they could be. Because PRISM is motivated
to address the registry question needs for a spectrum of registry
designs and diseases, it does contain registry data elements (in
actual use) that might not be ideally constructed or might
actually conflict with another value set. Regardless, the liberal
acceptance policy of PRISM increases the breadth and volume
of questions and ultimately increases the value of PRISM as a
central resource for questions (which should be supplemented
by advice on selection and use). We hope that others use PRISM
as a resource for standards development or build applications
that can facilitate the ranking or endorsement of certain PRISM
questions over others in specific diseases or contexts.
Search and Retrieval Requirements
As mentioned in the previous section, the growth of the library
brought with it challenges for curation and use. Internally, a
process was developed to add new content without duplicating
questions and ensure that related questions or variants could be
indexed for effective retrieval and comparison. We operated
under the assumption that PRISM needed to be useful to provide
value. We explored user roles and searching techniques to
determine the best method for indexing question and answer
sets (QAS). Our indexing scheme (including the use of
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controlled terminology) is described later. A key strategy for
identifying the search and retrieval requirements was employing
use cases.
The PRISM team developed narrative use cases (for question
searching, re-use, and new registry development) that have
informed our indexing approaches. For our indexing strategy,
PRISM also developed use cases of retrieval requirements as a
guide of needed functionality and detail, and leveraged existing
metadata and controlled vocabularies. The use cases describe
the development of new registries using PRISM as a resource
for the questions. Specifically, the use cases describe the
development of a prospective vasculitis and pregnancy
registry—including the re-use of PRISM questions and the
submission of new questions to PRISM—and the subsequent
development of another registry using these same
pregnancy-related questions. Finally, the use cases articulate a
demonstration and initial proof of the interoperability of data
collected from different registries and data sources. These
functional use cases ultimately will also support the evaluation
of PRISM. The use cases were developed by the authors and
not widely vetted in the rare disease community. They can be
found on PRISM website [25].
Indexing Model and Metadata
A critical and largely unaddressed problem for registries (and
clinical research data collection in general) is the need for patient
registry questions and answers to be indexed in such a way that
they can be retrieved for re-use, for example, to support rapid
development of another related rare disease registry. In essence,
indexing is the practice of applying metadata (structured and
descriptive information) to items in a database for efficient and
accurate retrieval [26]. An important measure of indexing is
specificity, which refers to the detail or precision of the indexing
process and its depth [26(p161)]. Achieving the appropriate
level of specificity in encoding the question and answer sets
was a continuous challenge. Our approach was guided by the
ideal situation where the pairs would be encoded to convey the
semantic meaning of the clinical concepts and at the same time
allow efficient collocation. The specificity and overall indexing
approach informed the detailed use cases discussed earlier. The
indexing scheme also addresses semantic ambiguities inherent
in research questions and answer sets, and includes metadata
for the following constructs:
1. Context (type of study, disease or treatment of interest, etc.)
2. Format of questions and location of semantics
3. Who is asking the question (patient, relative, doctor)?
4. Audience or person being asked the question (patient, family
member or caregiver)
5. Relevant data standards for specific answer sets
Metadata and Controlled Vocabularies
Metadata are used to describe information resource-type features
of questions, such as terms and attributes, and controlled
vocabularies represent the actual content. Both are important
for retrieval and, ultimately, interoperability. PRISM uses
Dublin Core (DC) as a metadata framework for indexing PRISM
QAS, and within DC metadata uses controlled terminology to
reflect the semantics for each question. Our approach is
described in detail in [27]. Terminology control, when
implemented correctly and consistently, can dramatically
improve the quality of search results in most contexts. SNOMED
CT is an ONC recommended standard for many aspects of the
electronic medical record, and previous research has indicated
that SNOMED CT is also well suited for clinical concepts in
research [28].
The use of Dublin Core metadata to annotate various QAS in
PRISM offers a way to employ the most appropriate controlled
vocabulary(s) for the content, while preserving retrievability.
In addition to selected Dublin Core metadata elements and
controlled terminologies, other decisions were made to ensure
that these elements and vocabularies were used appropriately
and consistently. Specifically, assuring each QAS is usable,
reproducible, and understandable on its own merit. For example,
a form that addresses gynecological issues may include a QAS
addressing menstrual symptoms, such as “Do you experience
cramps?” From the context of the form, this can refer only to
menstrual cramps and may be coded with or without the
“menstrual semantics”. However, when a later user searches
the registry for library questions about abdominal, leg or other
body site cramps, this question may be inappropriately selected.
The QAS metadata (including the embedded SNOMED CT
codes and the narrative definition of the question that PRISM
includes) can be used to easily disambiguate this term.
Under the leadership of terminology experts from the College
of American Pathologists, guidelines for using SNOMED CT
were developed related to post-coordination, selection of
hierarchies, and level of specificity. Guidelines for the use of
SCT within the PRISM Library data model were developed
collaboratively by the PRISM team and included the following
decisions:
1. Assigning codes for entire question and answer set groups
vs. discrete codes for questions and answers
2. An approach to take the (semantically) closest available
SNOMED CT concept rather than creating a new one
3. Consequently, we considered but rejected the idea to create
a SNOMED extension (“Ref Set”) mechanism
4. Versioning and change protocols were developed between
USF and CAP partners
Procedures for Adding New Items / Growing PRISM
content
As described in the previous section, PRISM has developed a
useful, consistent, and standards-compliant solution for the
encoding of questions in PRISM. Ultimately, the metadata
model and indexing strategy will be tested as the content of
PRISM grows. Implementation plans should ensure that as the
size of the PRISM library grows, duplicate questions are not
inadvertently added. (Anecdotally, this is an issue with other
question and metadata repositories, owing to the fact that a
complete search of existing content must be undertaken before
new content is added, and this search is both time-consuming
and generally not incentivized.) For PRISM to remain a useful
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resource to rare disease registry developers, and for PRISM to
support the goal to reduce question variation across rare disease
registries, the library should not contain obvious duplicates and
the library indexing model should be sufficient for users to
search and retrieve relevant registry questions from PRISM
before they re-create their own variation. As new content is
introduced to the PRISM outreach team at USF, they first
determine if the content is in scope of PRISM (ie, is not purview
of other standards initiatives shown in Table 1 and Table 2).
Then, as questions are identified for possible addition into the
library, library professionals perform multiple and semantically
enhanced queries to compare to QAS already in the database.
Through collaborations with rare disease stakeholders who are
part of the PRISM scientific review committee, they are then
edited for structure and clarity, and definitions are provided.
After the questions have been edited, semantic and
administrative metadata are applied (including controlled
terminology) before integrating them into the library’s database.
Discussion
Limited Scope
One of the biggest challenges of the PRISM project has been
to keep the scope reasonable and practical. Since the targeted
audience for PRISM is researchers and registry developers
(including PAGs with non-research backgrounds), we took a
minimalist approach to coding with the goal of easy retrieval.
It is our expectation that easy retrieval will drive increased
usage, which will cultivate de facto standards, and those
standards will ultimately support interoperability (see Figure
1).
We recognize that interoperability between registry questions
and other data (eg, EHR data) would require more sophisticated
coding with SNOMED CT and other data standards. Given the
short duration of this project and the desire for maximum
retrievability, we determined that this level of coding would be
out of the scope for PRISM at this time.
It is not clear at this point how large a corpus of sharable items
that there is among disparate and different rare diseases.
Likewise, it is still unclear whether items for rare diseases are
likely to be similar to items for more common diseases, and if
so, whether there would be value in finding a way to include
and reuse those items via PRISM as well. The future use and
evaluation of PRISM content by multiple disease representatives
will yield information on the reusability of the questions in
PRISM within and across rare and common diseases, as well
as provide practical examples of cross-disease standards and
determination of standards gaps. To understand the reusability
and generalizability of PRISM questions, additional work needs
to explore the validity and reproducibility of the categorization
and indexing of questions.
Figure 1. Theory of PRISM design to interoperability.
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The Future
PRISM fills a void for the rare diseases research and registry
development communities. The PRISM library resource can
support standardized data collection in patient registries by
reducing unnecessary variation. PRISM is free and available to
search through the project website [25]. Authors are also in the
process of making the PRISM library metadata model and
content accessible through the National Center for Biomedical
Ontology [29] Bioportal. While the library content is available,
we encourage innovators and developers to build tools that
integrate PRISM content into registry development efforts. It
is possible that the PRISM library resource could be leveraged
in large research data collection tools such as the NIH-funded
REDCap project.
Authors are hopeful for future funding that will allow PRISM
content to grow to meet the needs of the thousands of rare
diseases registry applications and to allow computer mediated
methods for adding and presenting content. The notion of using
a distributed community of registry developers to curate this
resource by commenting on and ranking items—as with the
demonstration of caDSR content that is described in [30]—is
very appealing. Such projects would require extensive marketing
and publicity of PRISM to a comprehensive group of rare
disease registry stakeholders and researchers in order to bolster
the extensive use of PRISM that would be required to effectively
demonstrate a bottom-up community driven development of
standards. An increased usage and future growth of PRISM will
in turn require formal governance for PRISM and official
policies related to content and a submissions and update
processes.
The PRISM developers, with the cooperation and support of
the National Organization for Rare Disorders (NORD), are
working to make the PRISM resource available and useful to
registry developers representing all rare diseases and all
countries. Currently, several rare disease patient advocacy
organizations are participating in focus groups and expert
interviews to inform the development of best interfaces and
retrieval strategies to ensure that PRISM is a useful and
accessible community-driven resource. In addition, we are
developing international collaborations to explore the translation
of items to support global rare disease research. Our overarching
goal is that—given the sheer number of rare diseases, the variety
of registry designs, and the number of languages that might
need to be addressed—the PRISM leadership seizes and
implements standards opportunities without burdening
resource-strapped rare disease communities.
Summary
The lack of a clear set of standards and specifications for data
collection using patient registries represents a significant data
standards gap in an explosively growing application
area—important to both drug development and patient-directed
health communities. Standardization of patient registries can
enable the interoperability of health and research data, as
registries should be able to receive data from health care system
or transmit data into various clinical research or
pharmacovigilance applications. PRISM can be used to facilitate
interoperability of existing and newly developed registries and
to ensure that moving forward, registries use standard sets of
questions. Without the use of such a resource, the proliferation
of patient registries and variation of data collection questions
will be inevitable. This central resource, the PRISM library,
will support a bottom-up and incremental standards
promulgation. By using a standard set of metadata elements and
SNOMED CT to facilitate the retrieval and re-use of existing
questions and standards, PRISM will reduce variation in the
rare diseases registry community and assist registry
implementers to produce high quality registries much more
efficiently than ever before. Once variation in patient registries
is reduced (ie, “standards” emerge), then issues related to
harmonizing, mapping, and relating to the different standards
communities for health care (eg, HL7) and research (eg, CDISC)
can be addressed in an efficient manner. In this approach, the
standardization of patient registry questions can serve to improve
efficiencies, collaboration, and resource sharing across the entire
drug development process.
Information regarding the development of PRISM and access
can be found on the PRISM website [24] .
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